Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43206   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-003148-38
    Sponsor's Protocol Code Number:1199.227
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-03-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-003148-38
    A.3Full title of the trial
    A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.
    Ensayo clínico aleatorizado, doble ciego controlado con placebo y de grupos paralelos de 12 semanas, seguido de una fase de 40 semanas con brazo activo único para evaluar el efecto de nintedanib oral 150mg dos veces al día sobre el recambio de los biomarcadores de matriz extracelular (MEC) en pacientes con fibrosis pulmonar idiopática y escasa disminución de la capacidad vital forzada (CVF).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effect of nintedanib on biomarkers
    Efecto de nintedanib en biomarcadores
    A.4.1Sponsor's protocol code number1199.227
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBoehringer Ingelheim España, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBoehringer Ingelheim España, S.A.
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBoehringer Ingelheim Pharma GmbH & Co. KG
    B.5.2Functional name of contact pointQRPE PSC CT Information Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressBinger Strasse 173
    B.5.3.2Town/ cityIngelheim am Rhein
    B.5.3.3Post code55216
    B.5.3.4CountryGermany
    B.5.4Telephone number+34934045100
    B.5.5Fax number+34934045580
    B.5.6E-mailclintriage.rdg@boehringer-ingelheim.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ofev
    D.2.1.1.2Name of the Marketing Authorisation holderBoehringer Ingelheim International GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1123
    D.3 Description of the IMP
    D.3.1Product nameOfev 100 mg capsule
    D.3.2Product code nintedanib
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnintedanib
    D.3.9.1CAS number 656247-17-5
    D.3.9.3Other descriptive nameNINTEDANIB
    D.3.9.4EV Substance CodeSUB120728
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ofev
    D.2.1.1.2Name of the Marketing Authorisation holderBoehringer Ingelheim International GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1123
    D.3 Description of the IMP
    D.3.1Product nameOfev 150 mg capsule
    D.3.2Product code nintedanib
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnintedanib
    D.3.9.1CAS number 656247-17-5
    D.3.9.3Other descriptive nameNINTEDANIB
    D.3.9.4EV Substance CodeSUB120728
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, soft
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, soft
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    E.1.1.1Medical condition in easily understood language
    idiopathic pulmonary fibrosis
    Fibrosis pulmonar idiopática
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level PT
    E.1.2Classification code 10021240
    E.1.2Term Idiopathic pulmonary fibrosis
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the trial will be to assess the effect of nintedanib on rate of change in extracellular matrix (ECM) turnover biomarker CRPM over 12 weeks which has shown to strongly associate with disease progression in patients with IPF in the PROFILE cohort.
    Evaluar el efecto de nintedanib en varios tipos de biomarcadores de recambio de la matriz extracelular (MEC) y el valor predictivo del cambio en estos biomarcadores de MEC sobre la progresión de la enfermedad.
    E.2.2Secondary objectives of the trial
    A secondary objective is to confirm the observed results from the PROFILE cohort, i.e. to assess the predictive value of change in extracellular matrix (ECM) biomarkers CRPM, C1M and C3M over 12 weeks for disease progression as defined by FVC decline ?10% or death over 52 weeks.
    Un objetivo secundario es confirmar los resultados observados del perfil cohorte,p ej, evaluar el valor predictivo del cambio en los biomarcadores de MEC (CRPM, C1M y C3M) durante 12 semanas sobre la progresión de la enfermedad definido como descenso de la FVC ?10% o muerte tras 52 semanas
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Written informed consent consistent with ICH-GCP and local laws, signed prior to participation in the trial including any study related procedures being performed;
    - Male or female patients aged =40 years at Visit 1;
    - A clinical diagnosis of IPF within the last 3 years from visit 0, based upon the ATS/ERS/JRS/ALAT 2011 guideline;
    - Chest high resolution computed tomography (HRCT) scan performed within 18 months of Visit 0;
    - Combination of HRCT pattern, and surgical lung biopsy pattern (the latter if available) as assessed by central review are consistent with the diagnosis of IPF;
    - FVC =80% of predicted normal at Visit 1.
    -Consentimiento informado escrito siguiendo la normativa local, firmado antes de la participación en el ensayo.
    -Pacientes varones o mujeres con edad ? 40 años en la visita 1
    -Diagnóstico clínico de IPF en función de la guía ATS/ERS/JRS/ALAT 2011 en los 3 años previos a la visita 0
    -HRCT realizada en los 18 meses previos a la visita 0
    -Confirmación del diagnóstico mediante revisión central de la HRCT torácica y biopsia pulmonar quirúrgica (la más reciente si está disponible) previa a la aleatorización
    -FVC ? 80 % del valor teórico de referencia en la visita 1 (selección).
    E.4Principal exclusion criteria
    - ALT, AST > 1.5 fold upper limit of normal (ULN) at visit 1;
    - Total bilirubin > 1.5 fold ULN at visit 1;
    - Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment);
    - Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC <0.7 at visit 1);
    - History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1;
    - Bleeding Risk:
    -- Known genetic predisposition to bleeding;
    -- Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin etc.) or high dose antiplatelet therapy;
    -- History of haemorrhagic central nervous system (CNS) event within 12 months prior to visit 1;
    -- History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1;
    -- International normalised ratio (INR) > 2 at visit 1;
    -- Prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of ULN at visit 1;
    - Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery;
    - History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1;
    - Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault formula at Visit 1;
    - Treatment with nintedanib, pirfenidone, azathioprine, cyclophosphamide, cyclosporine, any other investigational drug, n-acetylcysteine, prednisone/prednisolone >15 mg daily or >30 mg every 2 days OR use of other systemic corticosteroids as well as other investigational drugs within 4 weeks of visit 2;
    - Known hypersensitivity to nintedanib, peanut, soya or to any other components of the study medication;
    - Prior discontinuation of nintedanib treatment due to intolerability/ adverse events considered drug related;
    - A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial;
    - Alcohol or drug abuse which in the opinion of the treating physician would interfere with the treatment and would affect patient's ability to participate in this trial;
    - Patients not able to understand and follow study procedures such as but not limited to home spirometry, including completion of self-administered questionnaires without help;
    - Women who are pregnant, nursing, who plan to become pregnant while in the trial or female patients with positive ß-HCG test at visit 1 and/or visit 2;
    - Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly;
    - Patients with acute IPF exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 or during the screening period.
    Visit 1 and/or Visit 2 should be postponed in case of an IPF exacerbation or respiratory tract infection. Refer to Section 6.1 for information on re-scheduling of visits;
    - Patients who are currently participating in another trial or who have been participating in another trial within one month prior to Visit 1, and patients who have previously been enrolled in this trial.
    -ALT, AST > 1,5 veces el límite superior de la normalidad (ULN) en la visita 11.
    -Bilirrubina total > 1,5 veces el ULN en la visita 11.
    -Pacientes con enfermedad hepática crónica subyacente (Child Pugh A, B o C).
    -Obstrucción de las vías respiratorias relevante (es decir, FEV1/FVC < 0,70 antes de la broncodilatación [es decir, 70 %] en la visita 1).
    -Antecedentes de infarto de miocardio en los 6 meses previos a la visita 1 o angina de pecho inestable durante el mes previo a la visita 1.
    -Riesgo de hemorragia:
    ? Predisposición hemorrágica genética conocida.
    ? Pacientes que requieren fibrinólisis, dosis completa de tratamiento terapéutico anticoagulante (p. ej., antagonistas de la vitamina K, inhibidores directos de la trombina, heparina, hirudina, etc.) o un tratamiento antiagregante plaquetario en dosis altas2.
    ? Antecedentes de un episodio hemorrágico del sistema nervioso central (CNS) en los 12 meses previos a la visita 1.
    ? Antecedentes de hemoptisis o hematuria, hemorragia gastrointestinal activa o úlceras y/o lesión grave o cirugía en los 3 meses anteriores a la visita 1.
    ? Índice internacional normalizado (INR) > 2 en la visita 11.
    ? Tiempo de protrombina (PT) y tiempo de tromboplastina parcial (PTT) > 150 % del ULN en la visita 11.
    -Cirugía mayor3 programada durante la participación en el estudio, incluyendo trasplante pulmonar, cirugía abdominal o intestinal mayores.
    -Antecedentes de episodio trombótico (incluido ictus y accidente isquémico transitorio) en los 12 meses previos a la visita 1.
    -Aclaramiento de creatinina < 30 ml/min calculado según la fórmula de Cockcroft?Gault visita 1 (anexo 10.2).
    -Tratamiento con nintedanib, pirfenidona, azatioprina, ciclofosfamida, ciclosporina, cualquier otro producto en investigación, n-acetilcisteína, prednisona/prednisolona > 15 mg al día o > 30 mg cada 2 días O uso de otros corticosteroides sistémicos, así como cualquier otro fármaco en investigación en las 4 semanas previas a la visita 2.
    -Hipersensibilidad conocida a nintedanib, a los cacahuetes, a la soja o a cualquier otro componente de la medicación del estudio.
    -Suspensión del tratamiento con nintedanib en el pasado debido a intolerabilidad/acontecimientos adversos considerados como relacionados con el fármaco.
    -Enfermedad o afección que, en opinión del investigador, pueda interferir con los procedimientos del estudio o poner al paciente en riesgo al participar en este estudio.
    -Alcoholismo o toxicomanía que, en opinión del médico encargado del tratamiento, podrían interferir con el tratamiento y podrían afectar a la capacidad del paciente para participar en este estudio.
    -Pacientes que no pueden comprender y seguir los procedimientos del estudio, entre otras la espirometría domiciliaria6, incluida la cumplimentación sin ayuda de los cuestionarios que deben rellenar los propios pacientes.
    -Mujeres embarazadas, en periodo de lactancia o que prevean quedarse embarazadas durante el periodo del estudio o mujeres con una prueba de embarazo (ß-HCG) positiva en la visita 1 y/o en la visita 2.
    Pacientes con reagudización de la IPF o cualquier infección de las vías respiratorias en las cuatro semanas previas a la visita 1 o durante el periodo de selección.

    La visita 1 y/o la visita 2 deberán posponerse en caso de reagudización de la IPF o infección de las vías respiratorias. Véase el apartado 6.1 para obtener información sobre la reprogramación de visitas.
    Pacientes que estén participando o hayan participado en otro estudio con fármaco(s) en investigación en el mes anterior a la visita 1 y pacientes incluidos con anterioridad en este estudio.
    E.5 End points
    E.5.1Primary end point(s)
    1: The rate of change (slope) in blood CRPM from baseline to week 12.
    Tasa de cambio (pendiente) en la CRPM sanguínea desde el periodo basal hasta la semana 12.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1: 12 weeks
    1: 12 semanas
    E.5.2Secondary end point(s)
    The key secondary endpoint
    1: Proportion of patients with disease progression as defined by absolute FVC (% predicted) decline ?10% or death until week 52 based on in clinic supervised spirometry.

    Secondary endpoints:
    2: Rate of change (slope) in blood C1M from baseline to week 12 3: Rate of change (slope) in blood C3M from baseline to week 12.
    Criterio de valoración secundario fundamental:
    1: Porcentaje de pacientes con progresión de la enfermedad definida por una reducción de la FVC absoluta (porcentaje del valor teórico de referencia) ? 10 % o muerte hasta la semana 52.

    Criterios secundarios de valoración:
    2:Tasa de cambio (pendiente) en el C1M sanguíneo desde el periodo basal hasta la semana 12.
    3:Tasa de cambio (pendiente) en el C3M sanguíneo desde el periodo basal hasta la semana 12.
    Otros criterios de valoración (seleccionados):
    ? Tasa de cambio (pendiente) en la CRPM, el C1M y el C3M desde la semana 12 a la semana 52.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1: 52 weeks
    2: 12 weeks
    3: 12 weeks
    1: 52 semanas
    2: 12 semanas
    3: 12 semanas
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned13
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA68
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Japan
    Korea, Republic of
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days11
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months11
    E.8.9.2In all countries concerned by the trial days27
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 330
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state72
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 339
    F.4.2.2In the whole clinical trial 490
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    patients may be prescribed and continue taking nintedanib available on the market
    Los pacientes pueden ser prescritos y continuar tomando nintedanib disponible en el mercado
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-06-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-06-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-06-08
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA